Partner Mark Neuberger was quoted in a National Law Journal article, “3 Predictions After the Supreme Court’s Blow to Public-Sector Unions,” about the expected impact of the Supreme Court’s ruling that public-sector unions can’t force nonmembers to pay fees to cover collective bargaining costs.
Neuberger said the decision will continue a developing trend in the private sector, where a growing number of states have passed laws that outlaw all forms of mandatory union dues. “This decision will weaken the effectiveness, both economically but also politically, for all public sector unions in the 22 states that as of yesterday allowed compulsory agency fees,” he said. “On a grander scale, for good or for worse, this decision will lead to a further decline in the percentage of the American workforce that is unionized.”
Neuberger said the decision will continue a developing trend in the private sector, where a growing number of states have passed laws that outlaw all forms of mandatory union dues. “This decision will weaken the effectiveness, both economically but also politically, for all public sector unions in the 22 states that as of yesterday allowed compulsory agency fees,” he said. “On a grander scale, for good or for worse, this decision will lead to a further decline in the percentage of the American workforce that is unionized.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”